AUTHOR AND EDITOR INFORMATION

Section 1 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

INTRODUCTION

Section 2 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

Background

Homocystinuria is an inherited autosomal recessive defect in methionine metabolism that is caused by a deficiency in cystathionine synthase. This defect leads to a multisystemic disorder of the connective tissue, muscles, CNS, and cardiovascular system. Homocystinuria represents a group of hereditary metabolic disorders characterized by an accumulation of homocysteine in the serum and an increased excretion of homocysteine in the urine.

In 1960, the first case of homocystinuria was reported from Northern Ireland. The patient was initially described as having an unusual case of Marfan syndrome with renal abnormalities at age 7 years. He had recovered from acute glomerulonephritis at age 6 years and was found to be hypertensive the following year. The patient was mentally slow and thin and had fair hair, pale skin, and flushed cheeks. He had arachnodactyly, dolichostenomelia, pes cavus, a high arched palate, and bilaterally dislocated lenses. At age 10 years, the patient's urine was found to contain a large quantity of homocysteine; urinalysis results for the nitroprusside cyanide test were positive. The boy's left eye was enucleated because of a staphylococcal infection that occurred after acute pupillary-block glaucoma developed. His right lens became dislocated into the anterior chamber and had to be removed.

The patient's blood pressure readings normalized after his left kidney was removed when he was aged 13 years. Thick-walled internal arteries were noted at histologic examination. When pyridoxine supplementation was initiated at age 18 years, the patient's plasma homocysteine levels decreased below the reference range. Daily folic acid supplementation was added 1 year later because his plasma folate level was low. At age 20 years, the patient had a perforated duodenal ulcer. Chest pain occurred at age 27 years and recurred at age 34 years. The chest pain was considered to be angina and was successfully treated. At age 50 years, the patient's plasma homocysteine levels still remained low. The patient developed acute gout, which responded to indomethacin therapy.

Pathophysiology

Homocysteine is metabolized by means of 2 pathways: remethylation and transsulfuration.

The remethylation pathway comprises 2 intersecting biochemical pathways and results in the transfer of a methyl group (CH₃) to homocysteine from methylcobalamin, which receives its methyl group from S-adenosylmethionine (SAM), from 5-methyltetrahydrofolate (an active form of folic acid), or from betaine (trimethylglycine). Methionine can then be used to produce SAM, the body's universal methyl donor, which participates in several other key metabolic pathways, including the methylation of DNA and myelin.

The transsulfuration pathway of methionine/homocysteine degradation produces the amino acids cysteine and taurine. This pathway is dependent on adequate intake of vitamin B-6 and the hepatic conversion of vitamin B-6 into its active form, pyridoxal-5'-phosphate (P5P). The amino acid serine, which is a downstream metabolite generated from betaine via the homocysteine remethylation pathway is another necessary step.

Folate and vitamin B-12 are required for the remethylation of homocysteine to methionine. Findings from experimental studies have indicated that thyroid hormones affect folate metabolism. The observation that methylenetetrahydrofolate reductase is increased in hyperthyroidism and decreased in hypothyroidism may be relevant to the relationship between plasma homocysteine levels and thyroid status.

Women tend to have lower basal levels of homocysteine than do men, and neither contraceptives nor hormone replacement therapy seems to significantly alter the levels. Homocysteine concentrations are higher in postmenopausal women than in premenopausal women.

On the basis of the type of homocystinuria, the following 3 nosologic units are distinguished:

• Homocystinuria can be caused by the deficiency of cystathionine synthase. This is the classic form. The gene for this deficiency is located on chromosomal band 21q22.3. This unit includes the following forms: vitamin B-6 sensitivity (1.5% enzymatic activity), vitamin B-6 resistance (0% enzymatic activity), an intermediate variant, and a benign variant.
• Homocystinuria can be caused by insufficient vitamin B-12 synthesis resulting from a defect in the remethylation of homocysteine to methionine; methylmalonic aciduria is present.
• Homocystinuria can be caused by a deficiency in methylenetetrahydrofolate reductase. The methionine level is in the reference range.

Urine methionine and homocysteine levels are elevated because of deficient levels of cystathionine beta-synthase. In addition to this, at least 7 causes of homocystinuria are known: (1) defect in vitamin B-12 metabolism, (2) deficiency in N-5,10-methylenetetrahydrofolate reductase, (3) selective intestinal malabsorption of vitamin B-12, (4) homocystinuria responsive to vitamin B-12 (cobalamin [cbl] type E), (5) methylcobalamin deficiency with cbl type G, (6) type 2 vitamin B-12 metabolic defect, and (7) transcobalamin II deficiency.

The basis of the disease is a defect of the gene coding for L-serine dehydratase cystathionine synthase, which converts homocysteine and serine into cystathionine. Deficient activity of this enzyme has been demonstrated in liver extracts, in brain tissue, and in cultured skin fibroblasts and lymphocytes. The deficiency leads to an accumulation of homocysteine and methionine and to its conversion into homocysteine, which is excreted in the urine (Legal test results are positive). Alternatively, methionine is reformed and detectable in appreciable amounts in the urine and serum. The accumulation of homocysteine leads to damage of the collagen and elastic fibers. The binding of homocysteine to lysine residues results in the formation of thiazine bonds.

DL-homocysteine inhibits the production of tyrosinase, which is the major pigment enzyme. Increased concentrations of the methionine metabolite are toxic to the nervous system. Histologic analysis of brain tissue specimens from patients with homocystinuria reveals local foci of gliosis and necrosis.

In 1985, Mudd et al studied hybrid cells of human fibroblasts with normal cystathionine beta-synthase activity and hamster cells without enzyme activity and found that enzyme activity was co-segregated with chromosome 21. Two other enzymes involved in sulfur amino acid metabolism have been mapped: 5-methyltetrahydrofolate and L-homocysteine S-methyltransferase are mapped to chromosome 1, and cystathionase is mapped to chromosome 16. In cases of genetic deletion and partial trisomy, the levels of activity are consistent with the locus of cystathionine beta-synthase (CBS) between chromosomal bands 21q22.1 and 21q21. As reported in the study of fibroblasts, 3 types of cystathionine synthetase deficiency exist; these include types with reduced activity and normal affinity for P5P and types with reduced activity and reduced affinity for the cofactor.

The human CBS gene spans more than 30 kilobases and contains 19 exons. Three different 5' untranslated regions exist in the gene.

Molecular analysis of the methionine synthase reductase (MTRR) gene in one patient reveals compound heterozygosity for a transition c.1459G>A (G487R) and a 2–base pair (bp) insertion (c.1623-1624insTA). Another patient was homozygous for a 140-bp insertion (c.903-904ins140). The insertion is caused by a T>C transition within intron 6 of the MTRR gene, which presumably leads to activation of an exon splicing enhancer. These findings support the concept that this disorder is caused by mutations in the MTRR gene.

Four different mutations were identified in patients in the United Kingdom (c.374G>A, R125Q; c.430G>A, E144K; c.833T>C, I278T; c.919G>A, G307S) and 8 mutations were identified in patients from the United States (c.341C>T, A114V; c.374G>A, R125Q; c.785C>T, T262M; c.797G>A, R266K; c.833T>C, I278T; c.919G>A, G307S; g.13217A>C (del ex 12); c.1330G>A, D444N). The I278T was the predominant mutation in both populations. The spectrum of mutations observed in patients from the United Kingdom and the United States is closer to that observed in Northern Europe and bears less resemblance to that observed in Ireland.

Severe deficiency of glycine N-methyltransferase (GNMT) activity due to apparent homozygosity for a novel mutation in the gene encoding this enzyme that changes asparagine-140 to serine can be another cause of hypermethioninemia.

To date, 130 pathogenic mutations have been recognized in the CBS gene. In 2004, Orendae examined 10 independent alleles in Polish patients with cystathionine beta-synthase deficiency. They detected 4 already described mutations (c.1224-2A>C, c.684C>A, c.833T>C, and c.442G>A) and 2 novel mutations (c.429C>G and c.1039+1G>T). The pathogenicity of the novel mutations was demonstrated by expression in Escherichia coli. This is the first published communication on mutations leading to cystathionine beta-synthase deficiency in Poland.

Fibrillin-1 is a 350-kd calcium-binding protein that assembles to form 10- to 12-nm microfibrils in the extracellular matrix. The structure of fibrillin-1 is dominated by 2 types of disulfide-rich motifs, the calcium-binding epidermal growth factorlike and transforming growth factor beta binding proteinlike domains. Disruption of fibrillin-1 domain structure and function contributes to the pathogenic mechanisms of homocystinuria.

Methylmalonic aciduria and homocystinuria, cblC type, is the most frequent inborn error of vitamin B-12 metabolism. The gene responsible for cblC, MMACHC, has been identified. Several observations on ethnic origins were noted: the c.331C>T mutation is seen in Cajun and French-Canadian patients and the c.394C>T mutation is common in the Asiatic-Indian/Pakistani/Middle Eastern populations. The recognition of phenotype-genotype correlations and the association of mutations with specific ethnicities will be useful for identification of disease-causing mutations in cblC patients, for carrier detection, and for prenatal diagnosis in families in which mutations are known.

Frequency

United States

Homocystinuria is rare.

International

Homocystinuria rarely occurs. The worldwide frequency is reported to be 1 case per 344,000 population.

In Ireland, the frequency is higher, specifically 1 case per 65,000 population based on newborn screening and clinically detected cases. A surprisingly high prevalence of the CBS 833T-C mutation was detected among newborns who did not carry the 844ins68 variant, which is known to neutralize the 833T-CV mutation. This finding led some authors to suggest that the incidence of homocystinuria due to homozygosity for the mutation may be at least 1 case per 20,500 live births in Denmark.

Hypermethioninemia was reported in Korea in 2 compound heterozygous siblings with deficient activity of methionine adenosyltransferase (MAT) in their livers (MAT I/III deficiency). Molecular genetic studies demonstrate that each patient is a compound heterozygote for 2 mutations in MAT1A, the gene that encodes the catalytic subunit that composes MAT I and MAT III. These mutations include a previously known inactivating G378S point mutation and a novel W387X truncating mutation. W387X mutant protein, expressed in E coli and purified, has about 75% of wild-type activity.

Mortality/Morbidity

• The life expectancy of patients with homocystinuria is reduced.
• Almost one fourth of patients die as a result of thrombotic complications (eg, heart attack) before they are aged 30 years.

Sex

The disease is more common in males than in females.

Age

This condition is congenital.

CLINICAL

Section 3 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

History

• Neurologic features
• • An infant with homocystinuria is usually healthy, although thromboembolic complications of the CNS and psychomotor delay may occur during the first year of life.
  • A developmental delay is noted when patients are aged 2-3 years.
  • Psychiatric symptoms are also described in approximately one half of patients with homocystinuria.
  • Pyramidal symptoms, including muscle weakness due to an insult to the innervation of the pyramidal motor tract neurons, are occasionally observed in areas such as the leg.
• Skeletal and muscular features
• • The characteristic long thin extremities and arachnodactyly may not appear until late in childhood or during adolescence.
  • In contrast, osteoporosis, especially that of the spine, may have already been present for some time.
• Ophthalmologic features
• • Severe myopia is the first sign of ectopia lentis and may precede lens dislocation by several months to a year or even longer.
  • Once established, ectopia lentis progresses, even when good biochemical control is maintained.
• Vascular features
• • Thromboembolic events, such as cerebrovascular occlusions or pulmonary emboli, usually do not occur until adulthood but are reported in childhood and infancy.
  • Vascular occlusive disease is an important and serious feature.
• Other features
• • Homocystinuria produces high concentrations of amino acids that are competitive inhibitors of tyrosinase.
  • Accordingly, homocystinuria is associated with pale and pink skin. Occasionally, patients have malar rashes, fine fragile hair, and livedo reticularis.

Physical

Marfan syndrome is the primary differential diagnosis. Clinical features of homocystinuria, such as ectopia lentis, dolichocephalia, and chest and spinal deformities, are similar to the features found in patients with Marfan syndrome, although the cerebral symptoms, the changes in the hair, and the disorders of mental development are absent in patients with Marfan syndrome. Generalized osteoporosis, arterial and venous thrombosis, and mental retardation, which are features of homocystinuria, do not occur in patients with Marfan syndrome. In addition, homocysteine is not detectable in the urine of patients with Marfan syndrome.

Findings in homocystinuria include the following:

• Skin findings
• • Buccal skin shows red macules in children, adolescents, and adults, especially those living in warm environments.
  • Large pores are evident on the facial skin.
  • A livedolike pattern of blood vessels and atrophic, small, cigarette paper–like scars may be observed on the arms and hands.
  • Angiomata may develop in some patients.
  • DL-homocysteine inhibits tyrosinase, the major pigment enzyme. Hypopigmentation may be reversible in patients with pyridoxine-responsive homocystinuria.
  • The hair can have a coarse texture. Hair stained with acridine orange produces orange-red fluorescence, whereas healthy hair produces green fluorescence.
  • Hyperhidrosis, dry skin, and acrocyanosis may be present.
• Neurologic findings
• • Patients may behave aggressively.
  • Intelligence is slightly diminished, but in approximately one third of patients, intelligence is in the normal range.
  • Patients' mental capabilities have been reported to be higher in conditions that respond to pyridoxine supplementation than others.
  • Homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency may manifest with variable neurologic manifestations. Radiologic features include white matter changes (leukoencephalopathy).
  • Muscular hypotonia is characteristic.
  • Increased homocysteine levels have been detected in persons with neurological disorders such as Alzheimer disease, idiopathic Parkinson disease, Huntington disease, primary dystonia, and neural tube defects.
• Skeletal and muscular findings
• • Signs of Marfan syndrome, such as thin and long extremities, arachnodactylia, kyphoscoliosis, and deformations of the thorax, may be present.
  • Osteoporosis, genua valga, pectus carinatum (excavatum), and deformed teeth can be present.
  • The homocysteine concentration is an important risk factor for hip fractures in Parkinson disease patients receiving levodopa.
  • Inguinal and umbilical hernias are observed.
  • Muscular hypotonia is characteristic.
  • Spasms may occur.
• Ophthalmologic findings
• • Ophthalmologic findings are similar to those in patients with Marfan syndrome.
  • Ectopia lentis is an almost universal feature in patients older than 10 years, and it can even be present in newborns.
  • Other findings include myopia, iridopathy, cataracts, secondary glaucoma, and degeneratio (amotio) retinae.
  • Atrophy of the optic nerve, strabismus, nystagmus, or diminished convergence can occur in some patients.
  • Dislocation of the ocular lenses usually occurs in patients aged 4-10 years.
• Vascular findings
  • Vascular changes mainly affect the lower extremities. Fatal arterial and venous thromboses may occur.
  • Hyperhomocystinemia is an independent risk factor for atherosclerotic heart disease.
  • Patients with homocystinuria resulting from a deficiency of cystathionine beta-synthase have an increased risk of thrombosis when they also have the Leiden mutation for factor V.
  • Homocysteine induces tissue factor procoagulant activity in cultured human endothelial cells.
  • Reduced survival and abnormally rapid turnover of platelets, fibrinogen, and plasminogen have been noted in patients with homocystinuria.
• Other findings
  • A slightly foul odor of the urine is typical.
  • Spontaneous pneumothorax is reported in some adolescents with homocystinuria.
  • Pancreatitis is described as a complication of homocystinuria.
  • Increased homocysteine levels are implicated in a variety of other clinical conditions, including neural tube defects, spontaneous abortion, placental abruption, renal failure, diabetic microangiopathy, and premenstrual syndrome.
  • Children with autism might have lower baseline plasma concentrations of methionine, SAM, homocysteine, cystathionine, cysteine, and total glutathione and significantly higher concentrations of S-adenosylhomocysteine (SAH), adenosine, and oxidized glutathione. This metabolic profile is consistent with impaired capacity for methylation (significantly lower ratio of SAM to SAH) and increased oxidative stress (significantly lower redox ratio of reduced glutathione to oxidized glutathione) in children with autism. An increased vulnerability to oxidative stress and a decreased capacity for methylation may contribute to the development and clinical manifestation of autism.
  • Cystathionine beta-synthase is encoded on chromosome 21, and deficiency in its activity causes homocystinuria. The most common genetic cause of mental retardation is trisomy 21 or Down syndrome. The levels of cystathionine beta-synthase in the brains of persons with Down syndrome are approximately 3 times greater than those in healthy individuals. The over-expression of cystathionine beta-synthase may cause the developmental abnormality in cognition in Down syndrome children and that may lead to Alzheimer-type disease in Down syndrome adults.
  • Vascular disease is associated with increased plasma asymmetric dimethylarginine and homocysteine, and levels of both are increased in persons with renal failure. The relationship between hyperhomocystinemia and increased plasma asymmetric dimethylarginine may not be direct, but could be secondary do reduced renal function.
  • Snyderman reports a case of a homocystinuric patient with development of paraparesis and increasing liver failure. A liver transplantation was successful in achieving metabolic control without the need for any dietary restrictions.

Causes

See Pathophysiology.

DIFFERENTIALS

Section 4 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

Other Problems to be Considered

Marfan syndrome

WORKUP

Section 5 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

Lab Studies

• The diagnosis is based on the clinical picture and the results of laboratory analysis.
• The cyanide nitroprusside reaction in the urine is used as the Brand reaction.
• • In patients with positive screening test results, the diagnosis can be confirmed by analyzing methionine, homocysteine, and cystathionine levels by using paper chromatography, high-performance liquid chromatography (HPLC) with fluorescence detection, high-voltage electrophoresis, and amino acid tests.
  • The reference range methionine level is less than 1 mg/dL (30 µM). Homocysteine levels of up to 0.2 µmol/mL and methionine levels of up to 2 µmol/mL characterize cystathionine synthetase deficiency.
• Levels of homocysteine excreted in the urine are more than 200 mg, and the fraction of mixed bisulfite homocysteine and cysteine is established.
• In the liver, the enzymatic activity of cystathionine synthase is deficient. This reduced activity can be demonstrated in a liver biopsy specimen.
• Cultured fibroblasts derived from healthy skin, as well as from cells in the amniotic fluid, demonstrate cystathionine synthase activity, although the enzyme is not detectable in intact healthy skin. Fibroblasts grown from the skin of patients with homocystinuria are deficient in the enzyme.
• Heterozygous patients with homocystinuria have a dominant negative effect. The cblE type of homocystinuria is a rare autosomal recessive disorder, which manifests with megaloblastic anemia.
• The most widely used method for newborn screening for homocystinuria is a semiquantitative bacterial inhibition assay for measuring methionine concentration in dried blood spots (DBS). Because this method has resulted in a number of missed cases due to many factors, in 2004 Febriani developed an HPLC method with fluorescence detection to measure total homocysteine (tHcy) in DBS, which might be useful for newborn screening for homocystinuria. One disk of DBS, 3 mm in diameter, was sonicated in 10 minutes. The extract was reduced with dithioerythritol and was derivatized with 4-aminosulfonyl-7fluoro-2,1,3-benzoxadiazole before injection into HPLC. This method showed good linearity (r = 0.996), precision (coefficient of variation range 2.7-5%), and excellent correlation coefficient between DBS and serum tHcy, both in control (r = 0.932) and patient samples (r = 0.952).
• • By this method, the mean tHcy concentration in DBS of preterm newborns, full-term newborns, and adults was 1.4 ± 1.0, 2.5 ± 1.6, and 4.9 ± 1.5 µmol/L, respectively. The mean tHcy DBS concentrations in 2 cases of cystathionine beta-synthase deficiency and 1 case of 5,10-methylenetetrahydrofolate reductase deficiency were 22.7 ± 2.88, 29.3 ± 1.90, and 41.3 µmol/L, respectively.
  • This method, which is rapid, user friendly, and reliable, appears applicable to newborn screening of homocystinuria in place of methionine measurement.
• Serious complications of homocystinuria caused by cystathionine beta-synthase deficiency can be prevented by early intervention. In 2004, Refsum determined the prevalence of 6 specific mutations in 1133 newborn blood samples. These results suggest that homocystinuria is more common than previously reported. Newborn screening for homocystinuria through mutation detection should be further considered.
• The determination of thiodiglycolic acid levels in urine may help to characterize the metabolic imbalance of substances participating in methionine synthesis, which leads to hyperhomocystinuria. The determination of thiodiglycolic acid levels of the pretreated patient may indicate the degree of success of the treatment.
• Cystathionine beta-synthase plays a key role in the intracellular disposal of homocysteine and is the single most common locus of mutations associated with homocystinuria. Sen et al used hydrogen-exchange mass spectrometry to map peptides, whose motions are correlated with transmission of interasteric inhibition and allosteric activation. The mass spectrometric data provide an excellent correlation between kinetically and conformationally distinguishable states of the enzyme. A pathogenic regulatory domain mutant, D444N, is conformationally locked in 1 or 2 states sampled by the wild type of enzyme.

Imaging Studies

• With conventional MRI, the brain abnormalities are detected in cobalamin C/D defect and include unusual basal ganglia lesions, hydrocephalus, and supratentorial white matter abnormalities.

Other Tests

• Testing for heterozygosity may be valuable.
• • The results can be used to guide the use of preventative measures such as reduced methionine intake and pyridoxine supplementation.
  • Such testing is especially helpful in families of patients with homocystinuria.
• Electroencephalographic abnormalities may be reflected as increased intracerebral pressure.

Histologic Findings

DL-homocysteine inhibits the production of tyrosinase, which is the major pigment enzyme. Increased concentrations of the methionine metabolite are toxic to the nervous system. Histologic analysis of brain tissue specimens from patients with homocystinuria reveals local foci of gliosis and necrosis.

TREATMENT

Section 6 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

Medical Care

• The diagnosis should be established as early as possible. Neonates in whom homocystinuria is diagnosed have had a benign course when they are fed on methionine-restricted cysteine-supplemented diets. Cysteine can be supplemented to a maximum of 500 mg/d.
• The administration of pyridoxine in high doses (300-600 mg/d) is effective in some patients.
• Other possible treatments include the use of folic acid (in pharmacologic doses), betaine (3-methylglycine decreases serum concentrations of homocysteine), or cyanocobalamin, as well as symptomatic supportive measures.
• Homocysteine Reduction Formula, a special nutritional supplement created by Brimhall, can also lower homocysteine levels.
• In patients with hypothyroidism, treatment with L-thyroxine can normalize homocysteine levels.
• Betaine improves metabolic control in B6-nonresponsive patients with homocystinuria after optimum dietary control.
  • Betaine therapy can precipitate cerebral edema, although the exact mechanism is uncertain. Betaine does raise the methionine level, and cerebral edema can occur when plasma methionine values exceed 1000 µmol/L. Methionine levels must be monitored in patients with cystathionine beta-synthase deficiency who are on betaine; consider betaine as an adjunct, not an alternative, to dietary control.
  • However, even when patients' serum betaine concentrations are increased by supplementation, serum homocysteine concentrations are often not lowered to the reference range. Following a low-methionine diet that keeps serum methionine within the reference range may be necessary when treating patients with homocystinuria due to cystathionine beta-synthase deficiency when betaine is administered.
  • Conventional treatment of cystathionine beta-synthase deficiency by diet and pyridoxine/betaine normalizes many, but not all, metabolic abnormalities associated with cystathionine beta-synthase deficiency. The finding of low plasma serine concentrations in patients with untreated cystathionine beta-synthase deficiency may merit further exploration because supplementation with serine might be a novel and safe component of treatment of homocystinuria.

Surgical Care

• Surgical treatment should be considered, especially in patients with pupillary-block glaucoma or in those with recurrent lens dislocation into the anterior chamber.
• Other ophthalmologic or orthopedic disorders should be corrected.

Consultations

• An ophthalmologist should be consulted for the treatment of repeated lens dislocation, acute pupillary-block glaucoma, and other ophthalmologic disorders.
• An orthopedist should be consulted to correct orthopedic disorders.

Diet

• Patients must maintain a diet with limited amounts of protein (1 g/kg) and amino acid mixtures. The diet must be free of protein hydrolysate.
• Patients in whom the disease does not respond to pyridoxine supplements must be treated with dietary reductions in methionine and with cysteine supplementation.

MEDICATION

Section 7 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Drug Category: Dietary supplements

These agents are used to correct nutritional deficiencies.

Drug Name	Betaine anhydrous (Cystadane)
Description	Antihomocystinuric that acts as a methyl-group donor in the remethylation of homocysteine to methionine, removing excess homocysteine from the body.
Adult Dose	6 g/d PO divided bid; not to exceed 20 g/d
Pediatric Dose	<3 years: 100 mg/kg/d PO initially; increase weekly in 100-mg/kg increments; not to exceed 20 g/d >3 years: Administer as in adults
Contraindications	Documented hypersensitivity
Interactions	None reported
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Diarrhea and nausea; CNS changes

Drug Category: Vitamins

Vitamins are essential for normal DNA synthesis.

Drug Name	Cyanocobalamin (Cyomin, Crysti 1000, Crystamine)
Description	Deoxyadenosylcobalamin and hydroxocobalamin are active forms of vitamin B-12 in humans. Vitamin B-12 is synthesized by microbes but not by humans or plants.
Adult Dose	25-250 PO mcg/d
Pediatric Dose	Administer as in adults
Contraindications	Documented hypersensitivity; hereditary optic nerve atrophy
Interactions	None reported
Pregnancy	A - Safe in pregnancy
Precautions	Severe hypokalemia may result in vitamin B-12 megaloblastic anemia (may be fatal) because of increased cellular potassium requirements when anemia is corrected

Drug Name	Folic acid (Folvite)
Description	Important cofactor for enzymes used in red blood cell production.
Adult Dose	5 mg PO/IM/SC qd
Pediatric Dose	<12 years: Not established >12 years: 1 mg PO/IM/SC qd
Contraindications	Documented hypersensitivity
Interactions	Increased seizure frequency and subtherapeutic phenytoin levels reported with concurrent use
Pregnancy	A - Safe in pregnancy
Precautions	Benzyl alcohol (preservative in some preparations) associated with fatal gasping syndrome in premature infants; resistance to treatment possible with alcoholism and other vitamin deficiencies

FOLLOW-UP

Section 8 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

Complications

• Homocystinuria can cause pancreatitis.
• Homocystinuria may result in thromboembolic complications.
• Some authors speculate that inappropriate treatment might enhance CNS lesions of MAT I/III deficiency by causing a reversible vacuolating myelinopathy. Clinical symptoms (eg, mildly decreased appetite, sleepiness) and MRI findings (eg, abnormal T1 and T2 prolongations and reduced diffusion in the cerebral white matter) improved after discontinuation of therapy.

Prognosis

• The prognosis is favorable if patients use adequate diet alimentation.
• Nearly 25% of patients die before age 30 years.

REFERENCES

Section 9 of 9

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

• Alan L, Miller ND, Gregory S. Methionine and homocysteine metabolism and the nutritional prevention of certain birth defects and complications of pregnancy. Alt Med Rev. 1996;1:220-35.
• Augoustides-Savvopoulou P, Luka Z, Karyda S, et al. Glycine N-methyltransferase deficiency: a new patient with a novel mutation. J Inherit Metab Dis. 2003;26(8):745-59. [Medline].
• Baumgartner ER, Wick H, Maurer R, et al. Congenital defect in intracellular cobalamin metabolism resulting in homocysteinuria and methylmalonic aciduria. I. Case report and histopathology. Helv Paediatr Acta. 1979;34(5):465-82. [Medline].
• Confalonieri M, Parigi P, Scartabellati A, et al. Heterozygosity for homocysteinuria: a detectable and reversible risk factor for pulmonary thromboembolism. Monaldi Arch Chest Dis. Apr 1995;50(2):114-5. [Medline].
• Cruysberg JR, Boers GH, Trijbels JM, Deutman AF. Delay in diagnosis of homocystinuria: retrospective study of consecutive patients. BMJ. Oct 26 1996;313(7064):1037-40. [Medline].
• Febriani AD, Sakamoto A, Ono H, et al. Determination of total homocysteine in dried blood spots using high performance liquid chromatography for homocystinuria newborn screening. Pediatr Int. Feb 2004;46(1):5-9. [Medline].
• Finkelstein JD. Inborn errors of sulfur-containing amino acid metabolism. J Nutr. Jun 2006;136(6 Suppl):1750S-1754S. [Medline].
• Fowler B, Schutgens RB, Rosenblatt DS, et al. Folate-responsive homocystinuria and megaloblastic anaemia in a female patient with functional methionine synthase deficiency (cblE disease). J Inherit Metab Dis. Nov 1997;20(6):731-41. [Medline].
• Gahl WA, Bernardini I, Chen S, et al. The effect of oral betaine on vertebral body bone density in pyridoxine-non-responsive homocystinuria. J Inherit Metab Dis. 1988;11(3):291-8. [Medline].
• Ichinohe A, Kanaumi T, Takashima S, et al. Cystathionine beta-synthase is enriched in the brains of Down's patients. Biochem Biophys Res Commun. Dec 23 2005;338(3):1547-50. [Medline].
• James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. Dec 2004;80(6):1611-7. [Medline].
• Kim SZ, Santamaria E, Jeong TE, et al. Methionine adenosyltransferase I/III deficiency: two Korean compound heterozygous siblings with a novel mutation. J Inherit Metab Dis. Dec 2002;25(8):661-71. [Medline].
• Kraus JP. Komrower Lecture. Molecular basis of phenotype expression in homocystinuria. J Inherit Metab Dis. 1994;17(4):383-90. [Medline].
• Lawson-Yuen A, Levy HL. The use of betaine in the treatment of elevated homocysteine. Mol Genet Metab. Jul 2006;88(3):201-7. [Medline].
• Longo D, Fariello G, Dionisi-Vici C, et al. MRI and 1H-MRS findings in early-onset cobalamin C/D defect. Neuropediatrics. Dec 2005;36(6):366-72. [Medline].
• Moat SJ, Bao L, Fowler B, et al. The molecular basis of cystathionine beta-synthase (CBS) deficiency in UK and US patients with homocystinuria. Hum Mutat. Feb 2004;23(2):206. [Medline].
• Morel CF, Lerner-Ellis JP, Rosenblatt DS. Combined methylmalonic aciduria and homocystinuria (cblC): phenotype-genotype correlations and ethnic-specific observations. Mol Genet Metab. Aug 2006;88(4):315-21. [Medline].
• Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. Jan 1985;37(1):1-31. [Medline].
• Navratil T, Petr M, Senholdova Z, et al. Diagnostic significance of urinary thiodiglycolic acid as a possible tool for studying the role of vitamins B12 and folates in the metabolism of thiolic substances. Physiol Res. Feb 23 2006;[Medline].
• Nugent A, Hadden DR, Carson NA. Long-term survival of homocystinuria: the first case. Lancet. Aug 22 1998;352(9128):624-5. [Medline].
• Orendac M, Zeman J, Stabler SP, et al. Homocystinuria due to cystathionine beta-synthase deficiency: novel biochemical findings and treatment efficacy. J Inherit Metab Dis. 2003;26(8):761-73. [Medline].
• Orendae M, Pronicka E, Kubalska J, et al. Identification and functional analysis of two novel mutations in the CBS gene in Polish patients with homocystinuria. Hum Mutat. Jun 2004;23(6):631. [Medline].
• Refsum H, Fredriksen A, Meyer K, et al. Birth prevalence of homocystinuria. J Pediatr. Jun 2004;144(6):830-2. [Medline].
• Sakamoto A, Sakura N. Limited effectiveness of betaine therapy for cystathionine beta synthase deficiency. Pediatr Int. Jun 2003;45(3):333-8. [Medline].
• Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with ParkinsonĀ“s disease. Am J Med. Nov 2005;118(11):1250-5. [Medline].
• Scriver CR, Beaudet AL, Sly WS. The Metabolic and Molecular Bases of Inherited Diseases. 7th ed. New York, NY:. McGraw-Hill;1995.
• Sen S, Yu J, Yamanishi M, Schellhorn D, Banerjee R. Mapping peptides correlated with transmission of intrasteric inhibition and allosteric activation in human cystathionine beta-synthase. Biochemistry. Nov 1 2005;44(43):14210-6. [Medline].
• Singh RH, Kruger WD, Wang L, et al. Cystathionine beta-synthase deficiency: effects of betaine supplementation after methionine restriction in B6-nonresponsive homocystinuria. Genet Med. Mar-Apr 2004;6(2):90-5. [Medline].
• Snyderman SE. Liver failure and neurologic disease in a patient with homocystinuria. Mol Genet Metab. Mar 2006;87(3):210-2. [Medline].
• Tada H, Takanashi J, Barkovich AJ, et al. Reversible white matter lesion in methionine adenosyltransferase I/III deficiency. AJNR Am J Neuroradiol. Nov-Dec 2004;25(10):1843-5. [Medline].
• Tallur KK, Johnson DA, Kirk JM, et al. Folate-induced reversal of leukoencephalopathy and intellectual decline in methylene-tetrahydrofolate reductase deficiency: variable response in siblings. Dev Med Child Neurol. Jan 2005;47(1):53-6. [Medline].
• Whiteman P, Hutchinson S, Handford PA. Fibrillin-1 misfolding and disease. Antioxid Redox Signal. Mar-Apr 2006;8(3-4):338-46. [Medline].
• Wilcken DE, Wang J, Sim AS, et al. Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency: relevance of renal function. J Inherit Metab Dis. Feb 2006;29(1):30-7. [Medline].
• Yaghmai R, Kashani AH, Geraghty MT, et al. Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency. Am J Med Genet. Feb 15 2002;108(1):57-63. [Medline].
• Zavadakova P, Fowler B, Zeman J, et al. CblE type of homocystinuria due to methionine synthase reductase deficiency: clinical and molecular studies and prenatal diagnosis in two families. J Inherit Metab Dis. Oct 2002;25(6):461-76. [Medline].
• Zoccolella S, Martino D, Defazio G, et al. Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses. Curr Vasc Pharmacol. Jul 2006;4(3):237-43. [Medline].

Article Last Updated: Dec 6, 2006